• Anlotinib Hydrochloride: From Target to Phenotype

  2026-09-23

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor for cancer research. This article explains how to connect receptor inhibition with endothelial phenotypes—and how to interpret potency across biochemical, cellular, and tissue-level assays.

• Vincristine Sulfate: Reading Microtubule Assays

  2026-09-23

  Vincristine sulfate is more than a cytotoxic control: it is a mechanistic probe for microtubule dynamics, mitotic failure, and assay interpretation. This article presents a cross-domain evidence framework for connecting biochemical, cellular, and translational findings without overextending the data.

• SGI-1027, DNMT1, and RB1 in Gastric Cancer

  2026-09-22

  A 2024 Discovery Medicine study connects SGI-1027-mediated DNMT1 suppression with increased RB1 expression and reduced growth, migration, invasion, and metastasis in gastric cancer models. Its integrated cell and mouse experiments support a DNMT1–RB1 regulatory axis, while the absence of direct methylation and rescue assays defines important limits for mechanistic interpretation.

• FK866 (APO866): NAMPT Inhibition Guide

  2026-09-22

  FK866 (APO866) is a selective, non-competitive NAMPT inhibitor that reduces intracellular NAD and ATP in cancer-cell models. Its nanomolar potency, AML xenograft evidence, and defined storage and solubility profile support controlled hematologic cancer research, but the compound is not a clinical treatment.

• Angiotensin Peptides Enhance SARS-CoV-2 Receptor Binding

  2026-09-21

  The 2025 reference study shows that naturally occurring angiotensin peptides can differentially increase SARS-CoV-2 spike-protein binding to AXL, ACE2, and NRP1, with angiotensin III and angiotensin IV displaying stronger effects than several longer precursors. These findings connect peptide processing within the renin–angiotensin system to a testable mechanism of viral receptor engagement, while also highlighting the need for validation beyond antibody-based binding assays.

• FerroOrange for Live-Cell Fe²⁺ Detection

  2026-09-21

  FerroOrange is a live-cell Fe²⁺ fluorescent probe for resolving intracellular ferrous-ion changes across microscopy, flow cytometry, and plate-based assays. This workflow translates recent PM2.5–Fra2/LCN2 ferroptosis findings into practical macrophage experiments while emphasizing controls, assay limitations, and optimization.

• GSK 2837808A: LDHA Inhibition Workflow

  2026-09-20

  GSK 2837808A is a potent, selective LDHA tool for separating lactate production from broader glycolytic and immune effects. This workflow shows how to use it in hepatocellular carcinoma research and how to extend the lactate-focused assay logic cautiously into colorectal cancer metabolism research.

• GW4064 for Reliable FXR Cell Assays

  2026-09-19

  GW4064 (SKU B1527) provides a practical, evidence-based tool for studying FXR signaling in viability, proliferation, cytotoxicity, lipid, and fibrosis workflows. This scenario-driven guide covers assay interpretation, DMSO formulation, light protection, vendor selection, and how recent LX-2 cell evidence informs experimental design.

• GW4064: FXR Activation Workflow for Liver Research

  2026-09-18

  GW4064 is a non-steroidal FXR agonist for connecting receptor activation with bile acid transport, lipid phenotypes, and hepatocyte barrier integrity. This workflow combines potency-guided dosing, LC-MS transporter analysis, and tight-junction imaging to turn FXR activation into a testable mechanism rather than a single endpoint.

• Pef1 Labeling Reveals DNA Damage and Autophagy Links

  2026-09-18

  This preprint applies APEX2-based in vivo proximity labeling to Schizosaccharomyces pombe Pef1, a Cdk5 ortholog previously linked to lifespan and autophagy. The study identifies condition-dependent protein neighborhoods, validates a Pef1–Rad24 connection in the DNA damage response, and highlights actin and vesicle-trafficking proteins as candidates in autophagosome expansion.

• NAT1–ENO1–Lactate Axis in Colorectal Cancer

  2026-09-17

  A 2026 MedComm study links NAT1 loss to ENO1 activation, lactate accumulation, TRAF6-dependent PD-L1 stabilization, and immune escape in colorectal cancer. Its integrated database, multi-omics, cellular, patient, and mouse-model evidence provides a mechanistic framework for studying how metabolic interventions may improve immune checkpoint therapy, while remaining preclinical.

• Drug Response in Cancer: Growth Inhibition vs Death

  2026-09-17

  Hannah R. Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework for separating growth inhibition from cell death, improving interpretation of in vitro pharmacology and the design of follow-up experiments.

• CTCF Maintains Centromere Function in Mitosis

  2026-09-16

  The reference study uses rapid, inducible CTCF degradation to show that CTCF supports centromere architecture, metaphase chromosome alignment, and faithful mitotic division. Its findings distinguish a structural centromere defect from impaired CENP-E recruitment and provide a useful framework for interpreting mitotic phenotypes in cancer research.

• Oxaliplatin at the DNA–Immune Interface

  2026-09-16

  Oxaliplatin is a platinum-based chemotherapeutic agent whose DNA lesions provide a powerful framework for studying cancer chemotherapy, apoptosis, and treatment resistance. This article connects its assay applications with Wnt/β-catenin immune-evasion research while separating established evidence from testable combination hypotheses.

• Streptozotocin: From Diabetes Model to Neuropathy

  2026-09-15

  Streptozotocin and STZ are more than tools for hyperglycemia induction: they define the biological starting point for downstream diabetes research. This article connects β-cell injury with painful diabetic neuropathy assays and explains how to interpret neuroimmune findings without confusing model effects with therapeutic mechanisms.

7819 records 1/522 page Next 12345 下5页 Last page